|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Garcia M, Jernal A, Ward EM, et al: Global
Cancer Facts & Figures 2007. Journal. 2007.
|
|
3
|
Parkin DM, Pisani P and Ferlay J: Global
cancer statistics. CA Cancer J Clin. 49:33–64. 1999. View Article : Google Scholar
|
|
4
|
Bosch FX, Ribes J and Borras J:
Epidemiology of primary liver cancer. Semin Liver Dis. 19:271–285.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
El-Serag HB and Mason AC: Rising incidence
of hepatocellular carcinoma in the United States. N Engl J Med.
340:745–750. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nakakura EK and Choti MA: Management of
hepatocellular carcinoma. Oncology (Williston Park). 14:1085–1102.
2000.
|
|
7
|
El-Serag HB, Marrero JA, Rudolph L and
Reddy KR: Diagnosis and treatment of hepatocellular carcinoma.
Gastroenterology. 134:1752–1763. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Llovet JM, Ricci S, Mazzaferro V, et al:
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nigro JM, Baker SJ, Preisinger AC, et al:
Mutations in the p53 gene occur in diverse human tumour types.
Nature. 342:705–708. 1989. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Levine AJ, Momand J and Finlay CA: The p53
tumour suppressor gene. Nature. 351:453–456. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hollstein M, Sidransky D, Vogelstein B and
Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bressac B, Galvin KM, Liang TJ,
Isselbacher KJ, Wands JR and Ozturk M: Abnormal structure and
expression of p53 gene in human hepatocellular carcinoma. Proc Natl
Acad Sci USA. 87:1973–1977. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bourdon JC: p53 and its isoforms in
cancer. Br J Cancer. 97:277–282. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vousden KH and Lane DP: p53 in health and
disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar
|
|
15
|
Ozturk M: Genetic aspects of
hepatocellular carcinogenesis. Semin Liver Dis. 19:235–242. 1999.
View Article : Google Scholar
|
|
16
|
Tannapfel A, Busse C, Weinans L, et al:
INK4a-ARF alterations and p53 mutations in hepatocellular
carcinomas. Oncogene. 20:7104–7109. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bressac B, Kew M, Wands J and Ozturk M:
Selective G to T mutations of p53 gene in hepatocellular carcinoma
from southern Africa. Nature. 350:429–431. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Buendia MA: Genetics of hepatocellular
carcinoma. Semin Cancer Biol. 10:185–200. 2000. View Article : Google Scholar
|
|
19
|
Teramoto T, Satonaka K, Kitazawa S,
Fujimori T, Hayashi K and Maeda S: p53 gene abnormalities are
closely related to hepatoviral infections and occur at a late stage
of hepatocarcinogenesis. Cancer Res. 54:231–235. 1994.PubMed/NCBI
|
|
20
|
Ueda H, Ullrich SJ, Gangemi JD, et al:
Functional inactivation but not structural mutation of p53 causes
liver cancer. Nat Genet. 9:41–47. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pantoja E, Beecher TS and Cross VF:
Cutaneous lymphangiosarcoma of Stewart-Treves. Cutis. 17:883–886.
1976.PubMed/NCBI
|
|
22
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
|
23
|
Higashitsuji H, Itoh K, Nagao T, et al:
Reduced stability of retinoblastoma protein by gankyrin, an
oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat
Med. 6:96–99. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hsia CC, Di Bisceglie AM, Kleiner DE Jr,
Farshid M and Tabor E: RB tumor suppressor gene expression in
hepatocellular carcinomas from patients infected with the hepatitis
B virus. J Med Virol. 44:67–73. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Azechi H, Nishida N, Fukuda Y, et al:
Disruption of the p16/ cyclin D1/retinoblastoma protein pathway in
the majority of human hepatocellular carcinomas. Oncology.
60:346–354. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liew CT, Li HM, Lo KW, et al: High
frequency of p16INK4A gene alterations in hepatocellular carcinoma.
Oncogene. 18:789–795. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsuda Y, Ichida T, Matsuzawa J, Sugimura
K and Asakura H: p16(INK4) is inactivated by extensive CpG
methylation in human hepatocellular carcinoma. Gastroenterology.
116:394–400. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li DM and Sun H: PTEN/MMAC1/TEP1
suppresses the tumorigenicity and induces G1 cell cycle arrest in
human glioblastoma cells. Proc Natl Acad Sci USA. 95:15406–15411.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu TH, Huang CC, Lin PR, et al: Expression
and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in
hepatocellular carcinoma. Cancer. 97:1929–1940. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li QL, Ito K, Sakakura C, et al: Causal
relationship between the loss of RUNX3 expression and gastric
cancer. Cell. 109:113–124. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mori T, Nomoto S, Koshikawa K, et al:
Decreased expression and frequent allelic inactivation of the RUNX3
gene at 1p36 in human hepatocellular carcinoma. Liver Int.
25:380–388. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miyagawa K, Sakakura C, Nakashima S, et
al: Down-regulation of RUNX1, RUNX3 and CBFbeta in hepatocellular
carcinomas in an early stage of hepatocarcinogenesis. Anticancer
Res. 26:3633–3643. 2006.PubMed/NCBI
|
|
33
|
Li X, Zhang Y, Qiao T, et al: RUNX3
inhibits growth of HCC cells and HCC xenografts in mice in
combination with adriamycin. Cancer Biol Ther. 7:669–676. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nakanishi Y, Shiraha H, Nishina S, et al:
Loss of runt-related transcription factor 3 expression leads
hepatocellular carcinoma cells to escape apoptosis. BMC Cancer.
11:32011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tanaka S, Shiraha H, Nakanishi Y, et al:
Runt-related transcription factor 3 reverses epithelial-mesenchymal
transition in hepato-cellular carcinoma. Int J Cancer.
131:2537–2546. 2012. View Article : Google Scholar
|
|
36
|
Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ,
Xie JP and Thorgeirsson SS: Alterations of tumor suppressor genes
and allelic losses in human hepatocellular carcinomas in China.
Cancer Res. 54:281–285. 1994.
|
|
37
|
Kawai H, Suda T, Aoyagi Y, et al:
Quantitative evaluation of genomic instability as a possible
predictor for development of hepatocellular carcinoma: comparison
of loss of heterozygosity and replication error. Hepatology.
31:1246–1250. 2000. View Article : Google Scholar
|
|
38
|
Nishida N, Nagasaka T, Nishimura T, Ikai
I, Boland CR and Goel A: Aberrant methylation of multiple tumor
suppressor genes in aging liver, chronic hepatitis, and
hepatocellular carcinoma. Hepatology. 47:908–918. 2008. View Article : Google Scholar
|
|
39
|
Yang B, Guo M, Herman JG and Clark DP:
Aberrant promoter methylation profiles of tumor suppressor genes in
hepatocellular carcinoma. Am J Pathol. 163:1101–1107. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang Y, Wu MC, Sham JS, Zhang W, Wu WQ and
Guan XY: Prognostic significance of c-myc and AIB1 amplification in
hepatocellular carcinoma. A broad survey using high-throughput
tissue microarray. Cancer. 95:2346–2352. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shachaf CM, Kopelman AM, Arvanitis C, et
al: MYC inactivation uncovers pluripotent differentiation and
tumour dormancy in hepatocellular cancer. Nature. 431:1112–1117.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tada M, Omata M and Ohto M: Analysis of
ras gene mutations in human hepatic malignant tumors by polymerase
chain reaction and direct sequencing. Cancer Res. 50:1121–1124.
1990.PubMed/NCBI
|
|
43
|
Challen C, Guo K, Collier JD, Cavanagh D
and Bassendine MF: Infrequent point mutations in codons 12 and 61
of ras oncogenes in human hepatocellular carcinomas. J Hepatol.
14:342–346. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Stork P, Loda M, Bosari S, Wiley B,
Poppenhusen K and Wolfe H: Detection of K-ras mutations in
pancreatic and hepatic neoplasms by non-isotopic mismatched
polymerase chain reaction. Oncogene. 6:857–862. 1991.PubMed/NCBI
|
|
45
|
Weihrauch M, Benick M, Lehner G, et al:
High prevalence of K-ras-2 mutations in hepatocellular carcinomas
in workers exposed to vinyl chloride. Int Arch Occup Environ
Health. 74:405–410. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Davies H, Bignell GR, Cox C, et al:
Mutations of the BRAF gene in human cancer. Nature. 417:949–954.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
de La Coste A, Romagnolo B, Billuart P, et
al: Somatic mutations of the beta-catenin gene are frequent in
mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA.
95:8847–8851. 1998.PubMed/NCBI
|
|
48
|
Csepregi A, Rocken C, Hoffmann J, et al:
APC promoter methylation and protein expression in hepatocellular
carcinoma. J Cancer Res Clin Oncol. 134:579–589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Legoix P, Bluteau O, Bayer J, et al:
Beta-catenin mutations in hepatocellular carcinoma correlate with a
low rate of loss of heterozygosity. Oncogene. 18:4044–4046. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Huang S, He J, Zhang X, et al: Activation
of the hedgehog pathway in human hepatocellular carcinomas.
Carcinogenesis. 27:1334–1340. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nusslein-Volhard C and Wieschaus E:
Mutations affecting segment number and polarity in Drosophila.
Nature. 287:795–801. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Nybakken K and Perrimon N: Hedgehog signal
transduction: recent findings. Curr Opin Genet Dev. 12:503–511.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cohen MM Jr and Shiota K: Teratogenesis of
holoprosencephaly. Am J Med Genet. 109:1–15. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mullor JL, Sanchez P and Ruiz i Altaba A:
Pathways and consequences: Hedgehog signaling in human disease.
Trends Cell Biol. 12:562–569. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Stecca B, Mas C and Ruiz i Altaba A:
Interference with HH-GLI signaling inhibits prostate cancer. Trends
Mol Med. 11:199–203. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Patil MA, Zhang J, Ho C, Cheung ST, Fan ST
and Chen X: Hedgehog signaling in human hepatocellular carcinoma.
Cancer Biol Ther. 5:111–117. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Schaff Z, Hsia CC, Sarosi I and Tabor E:
Overexpression of transforming growth factor-alpha in
hepatocellular carcinoma and focal nodular hyperplasia from
European patients. Hum Pathol. 25:644–651. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hsia CC, Axiotis CA, Di Bisceglie AM and
Tabor E: Transforming growth factor-alpha in human hepatocellular
carcinoma and coexpression with hepatitis B surface antigen in
adjacent liver. Cancer. 70:1049–1056. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yamada T, De Souza AT, Finkelstein S and
Jirtle RL: Loss of the gene encoding mannose
6-phosphate/insulin-like growth factor II receptor is an early
event in liver carcinogenesis. Proc Natl Acad Sci USA.
94:10351–10355. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
De Souza AT, Hankins GR, Washington MK,
Orton TC and Jirtle RL: M6P/IGF2R gene is mutated in human
hepatocellular carcinomas with loss of heterozygosity. Nat Genet.
11:447–449. 1995.PubMed/NCBI
|
|
61
|
Dennis PA and Rifkin DB: Cellular
activation of latent transforming growth factor beta requires
binding to the cation-independent mannose 6-phosphate/insulin-like
growth factor type II receptor. Proc Natl Acad Sci USA. 88:580–584.
1991. View Article : Google Scholar
|
|
62
|
Kawate S, Takenoshita S, Ohwada S, et al:
Mutation analysis of transforming growth factor beta type II
receptor, Smad2, and Smad4 in hepatocellular carcinoma. Int J
Oncol. 14:127–131. 1999.PubMed/NCBI
|
|
63
|
Harley CB: Telomere loss: mitotic clock or
genetic time bomb? Mutat Res. 256:271–282. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Harley CB, Futcher AB and Greider CW:
Telomeres shorten during ageing of human fibroblasts. Nature.
345:458–460. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Counter CM, Avilion AA, LeFeuvre CE, et
al: Telomere shortening associated with chromosome instability is
arrested in immortal cells which express telomerase activity. EMBO
J. 11:1921–1929. 1992.PubMed/NCBI
|
|
66
|
Kim NW, Piatyszek MA, Prowse KR, et al:
Specific association of human telomerase activity with immortal
cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Counter CM, Hirte HW, Bacchetti S and
Harley CB: Telomerase activity in human ovarian carcinoma. Proc
Natl Acad Sci USA. 91:2900–2904. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Hiyama E, Gollahon L, Kataoka T, et al:
Telomerase activity in human breast tumors. J Natl Cancer Inst.
88:116–122. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Shay JW and Bacchetti S: A survey of
telomerase activity in human cancer. Eur J Cancer. 33:787–791.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Kojima H, Yokosuka O, Imazeki F, Saisho H
and Omata M: Telo merase activity and telomere length in
hepatocellular carcinoma and chronic liver disease.
Gastroenterology. 112:493–500. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Nagao K, Tomimatsu M, Endo H, Hisatomi H
and Hikiji K: Telomerase reverse transcriptase mRNA expression and
telomerase activity in hepatocellular carcinoma. J Gastroenterol.
34:83–87. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Namba M, Mihara K and Fushimi K:
Immortalization of human cells and its mechanisms. Crit Rev Oncog.
7:19–31. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
McCormick JJ and Maher VM: Towards an
understanding of the malignant transformation of diploid human
fibroblasts. Mutat Res. 199:273–291. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Linder S and Marshall H: Immortalization
of primary cells by DNA tumor viruses. Exp Cell Res. 191:1–7. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Schippers IJ, Moshage H, Roelofsen H, et
al: Immortalized human hepatocytes as a tool for the study of
hepatocytic (de-)differentiation. Cell Biol Toxicol. 13:375–386.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Strickler HD, Rosenberg PS, Devesa SS,
Hertel J, Fraumeni JF Jr and Goedert JJ: Contamination of
poliovirus vaccines with simian virus 40 (1955–1963) and subsequent
cancer rates. JAMA. 279:292–295. 1998.
|
|
77
|
Faller DV, Kourembanas S, Ginsberg D, et
al: Immortalization of human endothelial cells by murine sarcoma
viruses, without morphologic transformation. J Cell Physiol.
134:47–56. 1988. View Article : Google Scholar
|
|
78
|
Morgan TL, Yang DJ, Fry DG, et al:
Characteristics of an infinite life span diploid human fibroblast
cell strain and a near-diploid strain arising from a clone of cells
expressing a transfected v-myc oncogene. Exp Cell Res. 197:125–136.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Moriya K, Nakagawa K, Santa T, et al:
Oxidative stress in the absence of inflammation in a mouse model
for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res.
61:4365–4370. 2001.PubMed/NCBI
|
|
80
|
Ray RB, Meyer K and Ray R: Hepatitis C
virus core protein promotes immortalization of primary human
hepatocytes. Virology. 271:197–204. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Moriya K, Fujie H, Shintani Y, et al: The
core protein of hepatitis C virus induces hepatocellular carcinoma
in transgenic mice. Nat Med. 4:1065–1067. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Pfeifer AM, Cole KE, Smoot DT, et al:
Simian virus 40 large tumor antigen-immortalized normal human liver
epithelial cells express hepatocyte characteristics and metabolize
chemical carcinogens. Proc Natl Acad Sci USA. 90:5123–5127. 1993.
View Article : Google Scholar
|
|
83
|
Fukaya K, Asahi S, Nagamori S, et al:
Establishment of a human hepatocyte line (OUMS-29) having CYP 1A1
and 1A2 activities from fetal liver tissue by transfection of SV40
LT. In Vitro Cell Dev Biol Anim. 37:266–269. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Schaff Z, Kovalszky I, Nagy P, Zalatnai A,
Jeney A and Lapis K: Human and experimental hepatocarcinogenesis.
Scand J Gastroenterol (Suppl). 228:90–97. 1998. View Article : Google Scholar
|
|
85
|
Buchmann A, Ziegler S, Wolf A, Robertson
LW, Durham SK and Schwarz M: Effects of polychlorinated biphenyls
in rat liver: correlation between primary subcellular effects and
promoting activity. Toxicol Appl Pharmacol. 111:454–468. 1991.
View Article : Google Scholar
|
|
86
|
Jaworski M, Hailfinger S, Buchmann A, et
al: Human p53 knock-in (hupki) mice do not differ in liver tumor
response from their counterparts with murine p53. Carcinogenesis.
26:1829–1834. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Unger C, Buchmann A, Bunemann CL, Kress S
and Schwarz M: Wild-type function of the p53 tumor suppressor
protein is not required for apoptosis of mouse hepatoma cells. Cell
Death Differ. 5:87–95. 1998. View Article : Google Scholar : PubMed/NCBI
|
